Literature DB >> 15103750

Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair.

Marianne Gwechenberger1, Deddo Moertl, Richard Pacher, Martin Huelsmann.   

Abstract

AIM: Oncostatin-M, a member of the gp 130 family of cytokines, has been associated with inflammation, connective tissue production, and extracellular matrix turnover. Since the reperfused heart is associated with an intense inflammatory reaction followed by scar formation, we tested the hypothesis that oncostatin-M is upregulated in response to cardiac injury and may play a part in cardiac repair.
METHODS: Using a canine model of myocardial ischemia/reperfusion injury, we examined the expression of oncostatin-M at various time points of reperfusion, ranging from 1 h to 7 days. In situ hybridization was used to determine oncostatin-M mRNA expression. Immunohistochemistry was performed to detect oncostatin-M protein. Stimulatory effects of oncostatin-M on isolated endothelial cells and fibroblasts were investigated.
RESULTS: Oncostatin-M mRNA expression was detected in ischemic segments within the first 3 h of reperfusion and was persistent over the whole observation period. At the early time points, infiltrating and endothelial cells were the primary source of oncostatin-M mRNA expression. At later time points, macrophages and myofibroblasts were the main contributors. We previously demonstrated in vivo that monocyte-chemoattractant-protein (MCP-1) mRNA is induced early after reperfusion. We stimulated isolated endothelial cells with oncostatin-M and postischemic lymph, which have both upregulated MCP-1 expression in endothelial cells. In addition, isolated fibroblasts stimulated with oncostatin-M demonstrated a dose-dependent proliferative response.
CONCLUSION: Oncostatin-M may contribute to the process of healing after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15103750

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  8 in total

Review 1.  Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration.

Authors:  Marten Szibor; Jochen Pöling; Henning Warnecke; Thomas Kubin; Thomas Braun
Journal:  Cell Mol Life Sci       Date:  2013-12-10       Impact factor: 9.261

Review 2.  JAK redux: a second look at the regulation and role of JAKs in the heart.

Authors:  Mazen Kurdi; George W Booz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-28       Impact factor: 4.733

Review 3.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658

4.  OSM Enhances Angiogenesis and Improves Cardiac Function after Myocardial Infarction.

Authors:  Xiaotian Zhang; Di Zhu; Liping Wei; Zhijing Zhao; Xin Qi; Zongjin Li; Dongdong Sun
Journal:  Biomed Res Int       Date:  2015-06-04       Impact factor: 3.411

5.  Synthetic CpG oligonucleotides induce a genetic profile ameliorating murine myocardial I/R injury.

Authors:  Tobias Hilbert; Paul Markowski; Stilla Frede; Olaf Boehm; Pascal Knuefermann; Georg Baumgarten; Andreas Hoeft; Sven Klaschik
Journal:  J Cell Mol Med       Date:  2018-04-19       Impact factor: 5.310

Review 6.  The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure.

Authors:  Thomas Kubin; Praveen Gajawada; Peter Bramlage; Stefan Hein; Benedikt Berge; Ayse Cetinkaya; Heiko Burger; Markus Schönburg; Wolfgang Schaper; Yeong-Hoon Choi; Manfred Richter
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

Review 7.  The Role of Interleukin-6 Family Members in Cardiovascular Diseases.

Authors:  Yongqi Feng; Di Ye; Zhen Wang; Heng Pan; Xiyi Lu; Menglong Wang; Yao Xu; Junping Yu; Jishou Zhang; Mengmeng Zhao; Shuwan Xu; Wei Pan; Zheng Yin; Jing Ye; Jun Wan
Journal:  Front Cardiovasc Med       Date:  2022-03-23

8.  RUNX1: an emerging therapeutic target for cardiovascular disease.

Authors:  Alexandra Riddell; Martin McBride; Thomas Braun; Stuart A Nicklin; Ewan Cameron; Christopher M Loughrey; Tamara P Martin
Journal:  Cardiovasc Res       Date:  2020-07-01       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.